Nanobiotix S.A. (NBTX)
NBTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1760854/000176085426000003/0001760854-26-000003-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31. Converted from EUR at 0.8933 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | NBTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | France |
| IPO year | 2020 |
| SEC CIK | 0001760854 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | I0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $36.5M |
| Net income | -$26.8M |
| Operating income | Not in SEC XBRL data |
| Net margin | -73.5% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 29.9× |
Reported in EUR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-22 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-01 |
Source: SEC EDGAR submissions feed, 309 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.6% |
| 1 month | -39.7% |
| 3 months | -43.4% |
| Year to date | -8.0% |
| 1 year | -29.9% |
| From 52-week high | -61.4% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AMPH | Amphastar Pharmaceuticals Inc. | $26.05 | -2.65% | $1.1B |
| LBRX | LB Pharmaceuticals Inc | $34.79 | -3.17% | $1.1B |
| HROW | Harrow Inc. | $28.24 | -2.99% | $1.1B |
| TRAX | First Tracks Biotherapeutics Inc. Ordinary Shares | $31.68 | -6.96% | $1.1B |
| AVLN | Avalyn Pharma Inc. | $23.74 | -4.27% | $1.1B |
| JANX | Janux Therapeutics Inc. | $17.18 | -5.34% | $1.1B |
| LTGO | Latigo Biotherapeutics Inc. | $15.71 | -1.94% | $1.0B |
| DMRA | Damora Therapeutics Inc. | $18.56 | -8.37% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier